IL150571A0 - Novel chimeric proteins and methods for using the same - Google Patents

Novel chimeric proteins and methods for using the same

Info

Publication number
IL150571A0
IL150571A0 IL15057101A IL15057101A IL150571A0 IL 150571 A0 IL150571 A0 IL 150571A0 IL 15057101 A IL15057101 A IL 15057101A IL 15057101 A IL15057101 A IL 15057101A IL 150571 A0 IL150571 A0 IL 150571A0
Authority
IL
Israel
Prior art keywords
cell
methods
proteins
novel chimeric
chimeric proteins
Prior art date
Application number
IL15057101A
Other languages
English (en)
Original Assignee
Tr Associates L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tr Associates L L C filed Critical Tr Associates L L C
Publication of IL150571A0 publication Critical patent/IL150571A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL15057101A 2000-01-03 2001-01-03 Novel chimeric proteins and methods for using the same IL150571A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17425800P 2000-01-03 2000-01-03
PCT/US2001/000145 WO2001049318A1 (fr) 2000-01-03 2001-01-03 Proteines chimeres et procedes d'utilisation

Publications (1)

Publication Number Publication Date
IL150571A0 true IL150571A0 (en) 2003-02-12

Family

ID=22635474

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15057101A IL150571A0 (en) 2000-01-03 2001-01-03 Novel chimeric proteins and methods for using the same
IL150571A IL150571A (en) 2000-01-03 2002-07-03 New chimeric proteins and methods that utilize them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150571A IL150571A (en) 2000-01-03 2002-07-03 New chimeric proteins and methods that utilize them

Country Status (10)

Country Link
US (1) US7569663B2 (fr)
EP (2) EP1248645B1 (fr)
JP (1) JP4723782B2 (fr)
AT (1) ATE360031T1 (fr)
AU (1) AU2926401A (fr)
CA (1) CA2395945C (fr)
DE (1) DE60127933T2 (fr)
ES (1) ES2391760T3 (fr)
IL (2) IL150571A0 (fr)
WO (1) WO2001049318A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
CN1387538A (zh) 1999-01-15 2002-12-25 比奥根公司 针对tweak及tweak受体的拮抗剂和它们在治疗免疫性疾病中的应用
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
JP2004500844A (ja) * 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
WO2003086311A2 (fr) 2002-04-09 2003-10-23 Biogen, Inc. Procede pour traiter les etats lies a tweak
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
WO2005012363A1 (fr) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. Ciblage d'un inducteur d'inflammation
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
EP1885388B1 (fr) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Traitement et evaluation des troubles inflammatoires
WO2006138219A2 (fr) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
WO2008151088A2 (fr) 2007-06-01 2008-12-11 University Of Maryland, Baltimore Agents de liaison de récepteur fc de région constante d'immunoglobuline
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
MX2011004467A (es) 2008-10-31 2011-07-28 Biogen Idec Inc Moleculas de objetivo light y usos de las mismas.
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
CN102421913A (zh) 2009-03-13 2012-04-18 宾夕法尼亚大学董事会 Ox40/trail融合蛋白
TR201906652T4 (tr) 2010-07-28 2019-05-21 Gliknik Inc Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri.
WO2012042480A1 (fr) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions et procédés de traitement de malignités hématologiques
EP2736540B1 (fr) * 2011-07-29 2019-03-13 The Trustees Of The University Of Pennsylvania Récepteurs de commutation par costimulation
JP2015506372A (ja) * 2012-01-27 2015-03-02 グリックニック インコーポレイテッド ＩｇＧ２ヒンジドメインを含む融合タンパク質
MX2015002269A (es) 2012-08-20 2015-07-06 Gliknik Inc Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente.
AU2013371826A1 (en) * 2013-01-01 2015-08-13 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
EP2950814A4 (fr) 2013-01-31 2016-06-08 Univ Jefferson Protéines de fusion à base de pd-l1 et pd-l2 et leurs utilisations
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
CN106046170B (zh) * 2015-04-10 2020-07-10 中国医学科学院药物研究所 一种新型trail融合蛋白
JP2018512856A (ja) 2015-04-17 2018-05-24 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能な親和性を有する免疫調節タンパク質
SG10201913591SA (en) 2015-10-01 2020-02-27 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
EP3464347B1 (fr) 2016-06-07 2023-05-31 Gliknik Inc. Stradomères optimisés par la cystéine
KR20190095929A (ko) 2016-12-09 2019-08-16 글리크닉 인코포레이티드 다합체화 스트라도머인 gl-2045의 제조 최적화
KR102597943B1 (ko) 2017-01-05 2023-11-06 카 메디컬 리미티드 Pd1-41bbl 융합 단백질 및 이의 이용 방법
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CN110573522B (zh) 2017-01-05 2023-09-19 卡尔医学有限公司 SIRPα-41BBL融合蛋白及其使用方法
WO2018127916A1 (fr) 2017-01-05 2018-07-12 Kahr Medical Ltd. Protéine de fusion pd1-cd70 et ses procédés d'utilisation
CN110612119A (zh) 2017-02-07 2019-12-24 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
BR112019017713A2 (pt) 2017-02-27 2020-04-07 Shattuck Labs Inc proteínas quiméricas à base de csf1r
US11192933B2 (en) 2017-02-27 2021-12-07 Shattuck Labs, Inc. VSIG8-based chimeric proteins
WO2018157162A1 (fr) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Protéines chimères formées à partir de tigit et light
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
CN107267619A (zh) * 2017-07-04 2017-10-20 武汉波睿达生物科技有限公司 一种检测靶向cd33的cart细胞中car表达的荧光定量试剂盒
MA50360A (fr) 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
JP2021512147A (ja) 2018-01-22 2021-05-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． Ｃａｒ ｔ細胞の使用方法
AU2019301316A1 (en) 2018-07-11 2021-02-18 Kahr Medical Ltd. Sirpalpha-4-1BBL variant fusion protein and methods of use thereof
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
EP3997114A1 (fr) 2019-07-11 2022-05-18 KAHR Medical Ltd. Hétérodimères et procédés d'utilisation correspondants
WO2022036495A1 (fr) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations
WO2023019251A1 (fr) * 2021-08-12 2023-02-16 Baylor College Of Medicine Récepteurs leurres solubles modifiés pour améliorer l'immunothérapie contre le cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US6632789B1 (en) * 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds
WO1997033617A1 (fr) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Proteines hybrides de ligand fas et leurs utilisations
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.

Also Published As

Publication number Publication date
EP1908780B1 (fr) 2012-08-15
US7569663B2 (en) 2009-08-04
EP1248645B1 (fr) 2007-04-18
WO2001049318A1 (fr) 2001-07-12
US20030216546A1 (en) 2003-11-20
DE60127933D1 (de) 2007-05-31
EP1908780A1 (fr) 2008-04-09
EP1248645A1 (fr) 2002-10-16
AU2926401A (en) 2001-07-16
CA2395945C (fr) 2013-12-24
ATE360031T1 (de) 2007-05-15
JP4723782B2 (ja) 2011-07-13
ES2391760T3 (es) 2012-11-29
JP2003521485A (ja) 2003-07-15
IL150571A (en) 2010-11-30
DE60127933T2 (de) 2008-02-07
CA2395945A1 (fr) 2001-07-12
EP1248645A4 (fr) 2003-08-06

Similar Documents

Publication Publication Date Title
IL150571A0 (en) Novel chimeric proteins and methods for using the same
AU2003228962A1 (en) Ferritin fusion proteins for use in vaccines and other applications
WO2005021579A3 (fr) Peptides mimetiques epo et proteines de fusion
EP2277889A3 (fr) Protéines chimériques d'albumine et interféron beta
BG102343A (en) Recombinant anti-cd4 antibodies for therapy in hyman medicine
EP1127170A4 (fr) Anticorps monoclonaux humains du virus de l'hepatite c (vhc) pan
EP2298355A3 (fr) Protéines de fusion d'albumine
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
DE69531332D1 (de) Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert
WO1999040197A3 (fr) Variants du facteur angiogenique de croissance cellulaire endotheliale vasculaire vegf
NZ337955A (en) Modified TNF-alpha and their use as vaccines
CA2122714A1 (fr) Matieres contenant des proteines inactivant les ribosomes et methode pour leur preparation et leur utilisation
ES2159630T3 (es) Sistema de administracion por via oral de proteinas g-csf quimicamente modificadas.
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
WO2001064877A3 (fr) Gene humain de la schizophrenie
WO2002044197A3 (fr) Peptides de fixation des recepteurs des cytokines
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
WO2001064876A3 (fr) Gene humain de la schizophrenie
WO2003014293A3 (fr) Nouveaux analogues de polypeptides et proteines hybrides et leurs procedes d'utilisation
WO2000006735A8 (fr) HYBRIDES D'INTERFERON-$g(a)
WO2001002429A3 (fr) Angiopoietine 6 et ses utilisations
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
DE69730967D1 (en) Human dnase ii
WO2002044357A3 (fr) Procedes d'utilisation de 18903 dans le traitement de la douleur et des troubles lies a la douleur
AU2001251410A1 (en) 12303, a novel human twik molecule and uses thereof